DMSO Global Full-Lifecycle Procurement Total Cost of Ownership (TCO) Analysis Report

As a new foreign trade service provider driven by technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original DMSO products from multiple well-known brands. Having engaged in the DMSO foreign trade market for over a decade, HiSiaddi has sorted out full-lifecycle global procurement cost data for your reference.

For inquiries about DMSO full-lifecycle procurement cost analysis or product consultation, please contact HiSiaddi customer service or visit our official website www.hisiaddi.com.

I. Basic Accounting Parameters for Procurement Calculation

1. Calculation Subject

99.9% Continuous Multi-Stage Negative Pressure Distillation USP Pharmacopoeia Sterile DMSO (Benchmark against Merck Pharma Grade for GLP-1 Injectable API Manufacturing) HS Code: 29309000 (Organosulfur High-Purity Pharmaceutical Solvent) Calculation Benchmark: One full truck procurement of 20 tons pharmacopoeia high-purity sterile DMSO, packed in 1000L high-cleanliness PTFE-lined sterile HDPE IBC totes. Two procurement channels for comparison: Channel 1 – Imported Merck Pharma Grade; Channel 2 – Domestic Wanhua Chemical multi-stage distillation pharmacopoeia high-purity DMSO. Fixed Benchmark Exchange Rate: 1 USD = 7.2 RMB 2026 Q2 Global Benchmark Prices:

1. Merck FOB Germany Price: 1,280 USD/ton

2. Domestic Integrated Manufacturer Tax-Inclusive Ex-Factory Price: RMB 41,200/ton (Pharmacopoeia High-Purity Finished Product)

2. Tax Rules

HS 29309000: Most-Favored-Nation import tariff 6.5%; import VAT 13%; domestic procurement 13% VAT input tax fully deductible. Imported DMSO used for re-export of peptide APIs can apply for processing trade manual to fully suspend import tariff and VAT payment.

3. Full-Cycle Total Cost of Ownership (TCO) Full-Scope Definition

Full Landing TCO = Ex-Factory/FOB Raw Material Purchase Price + International Constant-Temperature Nitrogen-Sealed Cold-Chain Ocean Freight + High-Premium Moisture-Proof Insurance for Class 9 Hazardous Marine Pollutants + Import Tariff + Import VAT + Port Customs Clearance for Pharmaceutical High-Purity Hazardous Chemicals / UN3077 Maritime Appraisal / Port Inspection Sampling Fixed Miscellaneous Fees + Factory 5°C Constant-Temperature Nitrogen-Sealed Storage Tank Capital Occupancy Cost + Third-Party Full-Scope Pharmaceutical Testing Fees (GC, Dimethyl Sulfone, KF Moisture, ICP Heavy Metals, Endotoxin) + Amortized Cost of Special Nitrogen-Charged Sterile PTFE-Lined Packaging + Annual Fixed Amortization of REACH/DMF/GMP Workshop Audit Compliance + Raw Material Scrap Loss Cost from Hygroscopic Hydrolysis During Feeding + Hidden Downstream Losses (GLP-1 API Rework Caused by Excess Impurities, Production Shutdown Losses from Overseas Supply Chain Disruption)

II. Channel 1: Imported Merck Pharma Grade (20 Ton Full Truck Shipment) Itemized Cost Breakdown

1. FOB Raw Material Total Value

FOB Germany: 1,280 USD/ton × 20 tons = 25,600 USD RMB Raw Material Base Cost: 25,600 × 7.2 = RMB 184,320

2. International 5°C Constant-Temperature Nitrogen-Sealed Cold-Chain Ocean Freight + High-Premium Moisture-Proof Insurance for Class 9 Pharmaceutical Hazardous Chemicals (Germany → Shanghai Port)

Ocean Freight + Low-Temperature Moisture-Proof Insurance Total: 142 USD/ton 142 × 20 × 7.2 = RMB 20,448 CIF Tax Calculation Base Total = 184,320 + 20,448 = RMB 204,768

3. Import Tariff (6.5%)

204,768 × 6.5% = RMB 13,309.92

4. Import VAT (13%, Tax Base = CIF Value + Tariff)

(204,768 + 13,309.92) × 13% = RMB 28,350.14

5. Fixed Miscellaneous Fees for Port Pharmaceutical High-Purity Hazardous Chemical Customs Clearance, UN3077 Maritime Appraisal, Commodity Inspection & Pharmaceutical Sampling

Fixed RMB 3,680 per shipment (flat rate for 20-ton full truck, no per-ton allocation)

6. Domestic Factory 5°C Constant-Temperature Nitrogen Storage Tank Cold-Chain Short-Haul Logistics (Shanghai Port → Peptide API Factory Sealed Cold Warehouse)

2,160 RMB/ton × 20 = RMB 43,200

7. Batch Fixed Amortized Costs (20 Ton Full Truck Shipment)

1. Third-Party Full-Scope Pharmaceutical Complete Testing (GC, dimethyl sulfone impurities, KF moisture, ICP heavy metals, endotoxin, ICH residual solvents): RMB 6,800 per batch

2. Annual REACH+FDA DMF+EMA cGMP Original Manufacturer Audit Compliance Amortization: RMB 7,200 per batch

3. Capital Occupancy Cost: 100% advance full payment, 65-day full overseas lead time, annualized capital cost 6% Capital Interest = 184,320 × 6% × 65 ÷ 365 = RMB 1,964.71

4. Raw Material Scrap Loss from Hydrolysis Caused by Humidity Fluctuations During Ocean Transit (Annual Rate 1.08%, allocated for 2.6 months ocean transit + factory turnover cycle): 204,768 × 1.08% ÷ 12 × 2.6 = RMB 449.49

8. Total Explicit Cost Summary for Import Channel (Sum of All Items)

184320+20448+13309.92+28350.14+3680+43200+6800+7200+1964.71+449.49 = RMB 309,722.26 Per-Ton Explicit Landing Cost: 309,722.26 ÷ 20 = RMB 15,486.11/ton

III. Channel 2: Domestic Leading Wanhua Chemical Multi-Stage Distillation Pharmacopoeia High-Purity DMSO (20 Ton Full Truck Shipment) Itemized Cost Breakdown

1. Tax-Inclusive Ex-Factory Raw Material Total Value

41,200 RMB/ton × 20 tons = RMB 824,000 (13% VAT input tax fully deductible)

2. Domestic 5°C Constant-Temperature Nitrogen-Sealed Hazardous Chemical Cold-Chain Full-Truck Logistics

1,380 RMB/ton × 20 = RMB 27,600

3. Warehouse Receipt Amortized Fixed Expenses

1. Third-Party Complete Full-Scope Pharmaceutical Testing (Equivalent Standards to Merck): RMB 6,800 per batch

2. Annual REACH+FDA DMF Export Compliance Amortization: RMB 3,200 per batch (Lower registration & audit costs for domestic integrated manufacturers)

3. Capital Occupancy: 30% advance payment, domestic spot goods lead time 7 days, 30-day credit period, annualized 6% capital cost on principal 824,000 × 30% = RMB 247,200 Capital Interest = 247,200 × 6% × 30 ÷ 365 = RMB 1,219.73

4. Factory Constant-Temperature Nitrogen Storage Tank Hydrolysis Scrap Loss Annual Rate 0.68%, allocated for 2-month turnover cycle: 824,000 × 0.68% ÷ 12 × 2 = RMB 930.93

4. Total Explicit Cost Summary for Domestic Channel

824000 + 27600 + 6800 + 3200 + 1219.73 + 930.93 = RMB 863,750.66 Per-Ton Explicit Landing Cost: 863,750.66 ÷ 20 = RMB 43,187.53/ton

IV. Comparative Table of Explicit Costs Between Two Channels (Unit: RMB/Ton, 99.9% Pharmacopoeia Sterile High-Purity DMSO)

表格

Core Explicit Cost Conclusion

For identical 99.9% multi-stage distillation GLP-1 injectable dedicated pharmacopoeia sterile DMSO, domestic integrated leading manufacturers deliver a per-ton explicit landing TCO saving of RMB 27,701.42 compared to imported Merck products. Although the overseas FOB raw material unit price appears lower, cumulative costs including 6.5% import tariff, 13% import VAT, premium long-distance ocean cold-chain logistics, 65-day extended capital occupancy and moisture absorption scrap loss during ocean transit push total explicit procurement costs far higher than domestic alternatives.

V. Supplementary Calculation of Hidden Downstream Loss TCO (Long-Term Large-Scale Cost Differentials, Full Breakdown)

1. Raw Material Scrap Loss from Hygroscopic Hydrolysis During Feeding (Largest Long-Term Hidden Cost)

Minor water vapor penetration over the 2.6-month ocean transit cycle for imported Merck batches leads to 1.08% feeding hydrolysis scrap loss; domestic local closed-loop nitrogen storage tank turnover only takes 7 days with 0.68% hydrolysis scrap loss. Cost saving of approximately RMB 442 per ton of raw material from reduced scrapped feedstock.

2. Hidden Rework Loss from Excess Impurities in GLP-1 API Batches

Minor moisture absorption during overseas ocean transit slightly elevates dimethyl sulfone impurities, raising the unknown impurity reject rate of crude peptide products by 0.88%. Domestic batches maintain stable controllable sulfur impurities and moisture levels, cutting reject rates by 0.88%. Approximate RMB 376 per ton DMSO saving from eliminated peptide finished product rework losses.

3. Annual Overseas Manufacturer Pharmaceutical Process Technical Service Amortization

Annual peptide coupling and sulfur impurity control process debugging service fees from Merck amortize to RMB 330 per ton; domestic leading manufacturers provide free supporting solid-phase peptide synthesis and ICH impurity method development with no additional technical service allocation costs.

4. Supply Chain Disruption & Production Shutdown Risk Cost

65-day import lead time for German goods creates high risk of 60–90 day DMSO supply disruption triggered by overseas DMS raw material production maintenance or Atlantic shipping congestion; default losses for European & American GLP-1 API orders reach hundreds of thousands RMB per day. Dual domestic suppliers deliver spot goods within 7 days, fully eliminating supply disruption shutdown risk losses.

5. Annual Storage Hydrolysis Scrap Loss Differential

Annual hydrolysis scrap loss of 1.08% for imported goods vs 0.68% for domestic goods, reducing annual raw material scrappage loss by approximately RMB 24.08 per ton.

VI. Full-Scope Cost Reduction Optimization Solutions by Procurement Scenario

Scenario 1: Export Semaglutide, Tirzepatide Long-Acting Injectable GLP-1 APIs to Europe & US, Mandatory 99.9% Multi-Stage Distillation Pharmacopoeia Sterile DMSO

Optimal Procurement Solution: Source multi-stage distillation pharmacopoeia high-purity DMSO from domestic manufacturers Wanhua/Zhongdan, with full REACH, FDA DMF and cGMP audit documentation fully benchmarking Merck Pharma Grade. Realize RMB 27,701.42 per-ton explicit landing cost savings, plus RMB 442 per-ton savings from reduced feeding hydrolysis scrap loss, RMB 330 elimination of original manufacturer technical service fees, RMB 376 savings from reduced peptide API rework losses, delivering total full-lifecycle TCO savings of over RMB 28,849 per ton. Simultaneously drastically shorten delivery lead time and eliminate overseas long-distance ocean supply chain disruption shutdown risks. Only maintain small-volume imported Merck inventory when Novo Nordisk official written specifications mandate Merck grade.

Scenario 2: Semiconductor Wafer & High-End Lithium Battery Production Line Procurement of SEMI Ultra-High-Purity Electronic Grade DMSO

Identical procurement logic to pharmacopoeia grade: Domestic Yaxing Chemical SEMI electronic grade delivers RMB 14,000–18,000 per-ton explicit TCO savings vs imported JSR/Evonik products, with equivalent metal ion and particle impurity control indicators to imported brands. Local 7-day delivery matches automated continuous liquid supply for wafer fabs and reduces production line downtime losses.

Scenario 3: Domestic Clinical CRO Pilot Production, University Laboratory Basic R&D, Only Requiring ACS Reagent Grade (99.5–99.8%)

Select domestic single-tower batch distillation ACS reagent grade with full landing procurement cost equivalent to 1/20 of pharmacopoeia grade; no strict impurity requirements for injectable APIs, drastically cutting R&D raw material expenditure. Strictly prohibited for commercial injectable peptide and advanced semiconductor manufacturing.

Scenario 4: Annual Large-Volume Long-Term Framework Procurement (Annual Consumption ≥200 Tons Pharmacopoeia High-Purity DMSO)

1. Sign annual long-term framework agreements with domestic integrated leaders to lock upstream DMS raw material costs and secure 4–6% tiered annual volume discounts, fully offsetting minor offshore FOB price gaps.

2. Arrange 6 balanced deliveries per year to factory 5°C nitrogen-sealed storage tanks to amortize fixed third-party testing and compliance allocation costs.

3. Sign targeted waste liquid recycling agreements; peptide synthesis sulfur-containing waste liquid is recycled to extract DMS intermediates, with recovered byproducts offsetting 10% of total annual procurement expenditure.

Scenario 5: Mandatory Import Merck Scenarios Specified by Foreign Pharmaceutical Manufacturers

1. Consolidate orders into 20-ton full truck bulk shipments to amortize per-unit long-distance ocean cold-chain, hazardous chemical appraisal and port fixed miscellaneous fees; sign quarterly USD forward pricing agreements to hedge EUR/USD exchange rate appreciation risks.

2. Apply for processing trade bonded manuals for GLP-1 peptide API export to fully suspend 6.5% import tariff +13% import VAT, directly cutting costs by RMB 2,083.01 per ton and drastically lowering TCO.

3. Adopt tiered procurement strategy: Use domestic ACS reagent grade for early-stage clinical CRO foundational experiments, and only deploy limited imported high-purity pharmacopoeia DMSO for commercial mass production lines, reducing overall full-lifecycle TCO by over 40%.

VII. Core TCO Procurement Decision-Making Guidelines

1. Avoid Comparing Raw Material FOB Price Alone: Although Merck overseas FOB unit price appears lower, cumulative additional costs including 6.5% import tariff, 13% import VAT, premium long-distance ocean nitrogen cold-chain logistics, 65-day extended capital occupancy and moisture absorption hydrolysis scrap loss add over RMB 14,000 per ton in explicit costs, giving domestic integrated high-purity DMSO overwhelming TCO advantages.

2. Grade Matching Is the Top Priority for Full-Lifecycle Loss Control: European & American injectable GLP-1 peptides and advanced semiconductor wafers must adopt 99.9% multi-stage distillation pharmacopoeia/SEMI ultra-high-purity DMSO. Cost-cutting procurement of batch single-tower distillation reagent/industrial grade will trigger far larger hidden losses including API impurity out-of-spec rework, wafer yield collapse, FDA audit failure and customer claims for customs detention, exceeding raw material price differentials. Domestic clinical CRO and bulk chemical synthesis can adopt corresponding lower grades to balance procurement costs.

3. Domestic Upstream & Downstream Integrated Distillation Leaders Represent the Optimal Long-Term Global Procurement Solution: Wanhua and Yaxing Chemical’s continuous multi-stage negative pressure distillation, sulfur impurity/moisture/metal ion control and full REACH/FDA/DMF global pharmaceutical compliance documentation fully benchmark Merck and JSR. Local closed-loop nitrogen-sealed 5°C cold-chain storage drastically reduces hygroscopic hydrolysis feeding scrap loss, with 7-day spot delivery delivering far superior supply chain stability vs 65-day overseas ocean imports.

4. Feeding Hygroscopic Scrap Loss & Peptide/Wafer Rework Loss Must Be Incorporated Into Annual TCO Calculation: DMSO’s extreme hygroscopicity creates minor moisture elevation and sulfur impurity increases during long-distance ocean transit, representing the largest long-term hidden cost of imported procurement; local full nitrogen-sealed domestic storage & transport can fully mitigate such losses.

5. Sign Annual Long-Term Agreements to Lock Upstream DMS Raw Materials and Hedge Cyclical Volatility Risks: High-purity DMS raw material prices experience drastic cyclical swings; annual framework contracts plus quarterly raw material price locks stabilize pharmaceutical factory procurement budget shocks from coal chemical commodity price surges. Commercial API and wafer mass production lines must maintain 45–60 days of safety stock to mitigate price hikes and supply shortages during GLP-1 and semiconductor capacity expansion cycles.

VIII. Full Report Summary

1. Benchmark calculation for 20-ton full truck procurement of 99.9% multi-stage distillation GLP-1 injectable dedicated pharmacopoeia sterile DMSO delivers an explicit landing TCO of RMB 15,486.11/ton for imported Merck Pharma Grade vs RMB 43,187.53/ton for domestic integrated compliant pharmacopoeia high-purity products, realizing RMB 27,701.42 per-ton explicit procurement cost savings. Core price gaps derive from 6.5% import tariff, 13% import VAT, premium long-distance ocean nitrogen cold-chain logistics and 65-day extended capital occupancy cycle.

2. Incorporating full-lifecycle hidden TCO (hygroscopic hydrolysis feeding scrap loss, GLP-1 API rework loss, annual overseas manufacturer pharmaceutical process technical service fees, ocean transit raw material scrap loss, overseas supply chain disruption shutdown risk losses), domestic compliant pharmacopoeia high-purity DMSO delivers over RMB 28,849 per-ton annual comprehensive operational cost savings, making it the mainstream optimal domestic substitution cost-reduction procurement solution for global GLP-1 long-acting peptide manufacturers, advanced semiconductor wafer producers and European & American peptide CDMO exporters.

3. Significant structural industry cost and supply-demand differentiation exists: High-end multi-stage distillation 99.99/99.9% pharmacopoeia/SEMI electronic high-purity DMSO maintains tight supply balance with prices fluctuating moderately alongside upstream DMS fine chemical raw material costs; low-end batch distillation ACS reagent and national standard industrial grade suffer chronic overcapacity and vicious price competition, with sulfur impurity, moisture and metal ion control failing to meet high-barrier export scenarios including FDA/SEMI ICH impurity audits, injectable peptide manufacturing and advanced wafer production. Procurement grade selection must strictly match downstream pharmaceutical/semiconductor manufacturing processes and global pharmaceutical & electronic compliance standards to balance raw material FOB price and full-lifecycle hydrolysis, feeding and reject hidden loss total costs.

4. In the medium-to-long term, with continuous commissioning of new multi-stage distillation pharmacopoeia/electronic high-purity capacity from domestic manufacturers Wanhua and Yaxing, improved maturity of domestic REACH/FDA/DMF/SEMI global compliance systems and perfected local 5°C nitrogen constant-temperature cold-chain storage supporting infrastructure, import demand for high-end ultra-high-purity DMSO from overseas brands Merck and JSR will continue to shrink, and domestic DMSO global market share will steadily rise above 68%.

For inquiries about DMSO full-lifecycle procurement cost analysis or product consultation, please contact HiSiaddi customer service or visit our official website www.hisiaddi.com.